
## Edgar Filing: SCOLR Pharma, Inc. - Form 4

SCOLR Pharma Form 4	a, Inc.									
April 13, 2005 FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL		
Check this b	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,							3235-0287 January 31,	
if no longer subject to Section 16. Form 4 or Form 5									average urs per . 0.5	
obligations may continu <i>See</i> Instructi 1(b).	e. Section 17(	a) of the l	Public U	Itility Hol	ding Con		of 1935 or Section	on		
(Print or Type Resp	ponses)									
1. Name and Address of Reporting Person <u>*</u> LUCAS HERBERT L JR			2. Issuer Name <b>and</b> Ticker or Trading Symbol SCOLR Pharma, Inc. [DDD]				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (I	Middle)	dle) 3. Date of Earliest Transaction			(Check all applicable)				
C/O SCOLR P - 132ND AVE			(Month/) 03/31/2	Day/Year) 2005			X Director Officer (give below)		% Owner her (specify	
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)			1	<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
BELLEVUE, V	WA 98006						Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned	
	Transaction Date onth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8)	4. Securiti onAcquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Pamindar: Papart	on a separate line	for each al	ass of sec	Code V		(D) Price	. ,			
Reminder: Report	on a separate fille			unites bene	Perso inform requir	ns who res nation cont ed to resp ys a curre	spond to the collect tained in this form ond unless the for ntly valid OMB col	are not m	SEC 1474 (9-02)	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8.
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

## Edgar Filing: SCOLR Pharma, Inc. - Form 4



Herbert L. Lucas, Jr. by Gail Vitulli, Attorney-in-Fact	04/13/2005
<b>**</b> Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- In accordance with the Company's 2004 Equity Incentive Plan, Mr. Lucas elected to receive stock options (with an exercise price of 50%
   (1) of the average closing price of the common stock on the 10 trading days preceding the date of grant) in lieu of cash compensation for services as a director.
- (2) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(]